Meridian Bioscience (VIVO) Prelim. Q3 Revenue Misses Consensus

Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary results for its third quarter of fiscal 2022.

For the third quarter of fiscal 2022, preliminary unaudited net revenues are expected to be between $66 million and $69 million. The Diagnostics segment net revenues are expected to be between $41 million and $43 million. The Life Science segment net revenues are expected to be between $25 million and $26 million, of which sales of immunological reagents accounted for approximately 69% and molecular reagents contributed approximately 31%

(Consensus sees Q3 revenue of $69.6 million).

Meridian has not yet completed preparation of its interim financial statements for the third quarter of fiscal 2022 and the information presented herein is a preliminary estimate, subject to change.

You May Also Be Interested In

• GoPro to merge with Starman Optical in $285M recapitalization deal
• TDS drops bid for Array Digital Infrastructure minority shares
• Yatra board rejects Magna Holdings' $1.10-per-share tender offer